Company Overview and News
Commercial production in GRP’s new manufacturingunit kicked off on Wednesday. Earlier in April 2017, GRP had signed an agreement with a USA-based company for exclusive manufacture, process and supply of polymer composite products. Accordingly, the manufacturing facility was set up at one of its existing plants at Solapur in Maharashtra with production capacity of 850 million tonnes per annum (MTPA) at an investment of ₹2.
I am pleased to report another quarter of gains for Alluvial Fund, LP. For the quarter ended September 30, the partnership returned 7.4% versus 4.5% for the S&P 500 Index and 5.7% for the Russell 2000 Index. Year-to-date and since inception, our partnership has returned 21.0% compared to the S&P 500 Index's 14.2% and the Russell 2000 Index's 10.9%.
Singer India gained 2.23% to Rs 250 at 09:18 IST on BSE after the company scheduled a board meeting on 6 November 2017, to consider stock-split of equity shares.
By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about various products, offers and services provided by IIFL through any mode including telephone calls, SMS, letters etc. . you confirm that laws in relation to unsolicited communication referred in “National Do Not Call Registry” as laid down by “Telecom Regulatory Authority of India” will not be applicable for such information/ communication.
WILLEMSTAD, Curaçao, Oct. 2, 2017 /PRNewswire/ -- Retail Holdings N.V. (Symbol: RHDGF) -- Retail Holdings N.V. ("Retail Holdings", together with its subsidiaries and affiliates, the "Company"), announced that the Retail Holdings Board of Directors had approved today an initial 2018 distribution of $9.00 per Common Share to Shareholders of record on January 4, 2018, to be paid on or about January 10, 2018.
WILLEMSTAD, Curaçao, Aug. 15, 2017 /PRNewswire/ -- Retail Holdings N.V. (Symbol: RHDGF) -- Retail Holdings N.V. ("Retail Holdings", together with its subsidiaries and affiliates, the "Company") announced today results for the first half of 2017.
Retail Holdings N.V. (OTCPK:RHDGF), hereafter referred to as REHO, is a Curacao based holdco that is trading on the pink sheets.
Retail Holdings N.V. (the "Company"), announced that it's 54.1% owned subsidiary, Sewko Holdings Limited, has placed additional shares of the Company's listed operating subsidiaries. In Bangladesh, an additional 4,616,833 shares were placed, reducing the Company's equity stake in Singer Bangladesh Limited to 64.1%. In India, 278,942 shares were sold, reducing the Company's equity stake in Singer India Limited to 72.
Retail Holdings N.V. (the "Company"), reported very strong growth for 2016 at the Company's two principal operating subsidiaries, Singer Bangladesh Limited ("Singer Bangladesh") and Singer (Sri Lanka) PLC ("Singer Sri Lanka").
WILLEMSTAD, Curacao, Aug. 12, 2016 /PRNewswire/ -- Retail Holdings N.V. (Symbol: RHDGF) -- Retail Holdings N.V. ("Retail Holdings", together with its subsidiaries and affiliates, the "Company") announced today results for the first half of 2016.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...